Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions

doi:10.4252/wjsc.v6.i2.69

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6865)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

379

WORD

341

HTML

3793

Figures (1-1)

199

Tables (1-2)

251

Sum=4963

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

986

Download

916

Sum=1902

Apr 26, 2014 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Stem Cells. Apr 26, 2014; 6(2): 69-81
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.69

Open in New Tab Full Size Figure Download Figure

Figure 1 Clinically useful algorithm for optimal consolidation for acute myeloid leukemia patients based on cytogenetic and molecular genetic aberrations, based on available data and practice preference. ¹Allogeneic HCT may be considered in medically fit AML patients with intermediate risk/normal cytogenetics in CR1. Bu/Cy: Busulfan/cyclophosphamide; CEBPA: CCAAT enhancer binding protein alpha; CR: Complete remission; dUCB: Double umbilical cord blood; FLT3-ITD: FMS-like tyrosine kinase 3 gene-internal tandem duplication; HCT-CI: Hematopoietic cell transplantation-comorbidity index; HDT: High dose therapy; HiDAC: High dose cytarabine; NPM: Nucleophosmin.

Citation: Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells 2014; 6(2): 69-81
URL: https://www.wjgnet.com/1948-0210/full/v6/i2/69.htm
DOI: https://dx.doi.org/10.4252/wjsc.v6.i2.69